Guidelines

Guidelines are key to modern health and medical practice. Their recommendations are evidence-based and cover a wide range of topics - managing specific conditions, use of medicines in different settings or services and interventions to improve health.

We are keen to publicise the efforts and outputs of all our guideline Working Groups where we can. Guidelines in Practice publicise expert content on best clinical practice to primary care health professionals. They recently used our guidelines as an example of their value in ‘Accredited guidance promotes excellence in rheumatology’. Elsewhere, they are also covered the BSR Guideline on tocilizumab in RA and how it could help practitioners and commissioners.

Below are three tables that set out the current status of all of BSR’s guidelines. New ones are being developed whilst others that already exist may be undergoing minor or major revisions. The remainder are in current use.

NICE has accredited the process used by BSR to produce its clinical guidance. Accreditation is valid for 5 years from February 2013.


For full details on our accreditation, visit nice.org.uk/accreditation.

Current guidelines Produced Due for revision
 
BSR and BHPR guideline for the treatment of systemic sclerosis 

Executive summary
Full guidelines

2016
NICE accredited
2019
Prescribing for rheumatological conditions in pregnancy and breastfeeding.
Part I: standard and biologic disease modifying anti-rheumatic drugs and 
           corticosteroids.
 
Part II: analgesics and other drugs used in rheumatology practice.

2016
NICE accredited
 2019
Management of Adults with ANCA associated vasculitis 
BSR and BHPR guidelines for the management of adults with ANCA-associated vasculitis

Executive summary
Full guidelines
2014
NICE accredited
2016
Use of IV Tocilizumab in the treatment of adults with RA 

Executive summary
Full guidelines
2013
NICE accredited
2017
Treatment of psoriatic arthritis with biologics 

June 2016: This guideline was due for revision.  After discussion with members of the Working Group who created it, it has been decided that a review of the guideline should be postponed until 2017. Here is the explanatory Statement by Dr E MacPhie, SAGWG Chair.

Executive summary
Full guidelines
Audit tool
2013
NICE accredited
2017
Management of the hot swollen joint in adults 

Executive summary
Full guidelines 
Revision statement
2006
Renewed and accepted unchanged in 2012
2016
Management of polymyalgia rheumatica

SAGWG decided that the 2009 guideline, originally due for review in 2015, remains current. It is substantially the same as the new 2015 EULAR ACR guideline: Recommendation for the Management of Polymyalgia Rheumatica.
 

Executive summary 
Full guidelines
2009 2018


Guidelines under revision Due for publication
Safety of anti-TNF therapies in RA 

Executive summary 
Full guidelines
2017
The use of Rituximab in rheumatoid arthritis 

Executive summary 
Full guidelines
2016
Management of Giant Cell Arteritis 

Executive summary
Full guidelines 
2016
Guidelines for disease-modifying anti-rheumatic drug (DMARD) therapy 

Executive summary 
Full guidelines
2016
Management of Gout 

Executive summary 
Full guidelines
2016


New guidelines in development Due for publication
Ankylosing spondylitis/spondyloarthropathies and biologics Q1 2016
Management of SLE
Management of Sjögren’s Syndrome